The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.

Daniela Josabeth López-CanoDaniel Cadena-SandovalOlga Beltrán-RamírezRosa Elda Barbosa-CobosFausto Sánchez-MuñozLuis Manuel Amezcua-GuerraYaneli Juárez-VicuñaMaría Concepción Aguilera-CartasJosé MorenoJesús Bautista-OlveraGuillermo Valencia-PachecoRicardo F López-VillanuevaJulián Ramírez Bello

Published in: Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2017)

Our data provide the first demonstration that PTPN22 R620W confers GD susceptibility among Latin-American patients. Moreover, this is the second report documenting the association of PTPN22 R263Q with protection against SLE and RA.

Keyphrases

systemic lupus erythematosus
disease activity
rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
ankylosing spondylitis
electronic health record
machine learning
big data
deep learning
artificial intelligence